Circulogene Theranostics Taps Station X to Power Genomic Data Interpretation for Finger-Stick Liquid Biopsy Services
December 01 2015 - 7:45AM
Business Wire
GenePool from Station X provides a genome management platform
that generates custom reports from cell-free DNA sequencing for
clinicians evaluating and monitoring patient tumors
Station X, Inc., a leading developer of cloud-based genome
management systems for research and precision medicine
applications, today announced that Circulogene Theranostics will
use its GenePool® platform to analyze and interpret data generated
from their cell-free DNA (cfDNA) sequencing-based liquid biopsy
services. Circulogene’s proprietary technology is capable of
detecting nearly 3,000 cancer mutations on 50 well-established
cancer-associated genes and can provide information on current
FDA-approved and NCCN/ASCO-endorsed treatment options for the tumor
DNA mutations identified.
“Circulogene’s liquid biopsy tumor DNA sequencing is the only
test available that combines finger-stick volumes of blood and the
most advanced next-generation sequencing to monitor tumor mutant
DNA within well-characterized, well-documented cancer-associated
genes,” said Circulogene CEO Mike Mullen. “Station X has been
instrumental in helping us build our genomic data analysis and
reporting workflow. GenePool was the only solution with the
flexibility and power to quickly analyze our unique sequencing data
and generate reports that aid our clinician customers in planning,
implementing and monitoring a patient’s treatment process.”
GenePool from Station X is a secure platform-as-a-service that
enables life science and healthcare organizations to integrate,
analyze, visualize and manage patient-derived genomic information
more efficiently and effectively. GenePool is pre-loaded with
standard clinical reporting capabilities for incidental findings
and tumor profiling, but its flexibility means organizations like
Circulogene can customize GenePool for use with their proprietary
gene or variant testing panels and annotations. GenePool also
provides a convenient and dynamic way to securely store patient
data for updated reporting, ongoing monitoring and for
investigating the aggregated information.
“Leading clinical diagnostic laboratories are adopting GenePool
based on its flexible design, demonstrated scalability, and speed
in performing deep comparative analyses and generating medically
relevant insights,” said Richard Goold, CEO and Co-Founder of
Station X. “Our work with Circulogene is an excellent example of
how GenePool allows diagnostic laboratories to focus on test
innovation and support their customers by leveraging our expertise
in genome management and interpretation. We are very proud of our
work with Circulogene and are confident that the insights they
deliver will help establish liquid biopsies as a new gold standard
in cancer care.”
Through GenePool, Circulogene can analyze data across multiple
dimensions and develop custom reports supported by rich and
ever-growing content libraries such as The Cancer Genome Atlas
(TCGA), Cancer Cell Line Encyclopedia, ClinVar, COSMIC, dbSNP, FDA
Pharmacogenomics Biomarkers, PharmaADME, and many others.
Configurable workflows and annotations are supported by interactive
visualization tools and a robust Genome Browser. Through a flexible
API, GenePool seamlessly integrates with existing LIMS systems and
leading cloud-based storage, compute, and data processing
technologies from Amazon Web Services, DNAnexus, Google Cloud
Platform, Illumina BaseSpace, Microsoft Azure and Seven Bridges
Genomics, among others.
GenePool is available directly from Station X. For more
information, please visit www.stationxinc.com.
About Station X
Station X helps life science and healthcare organizations solve
integration, collaboration, analysis, visualization, and reporting
challenges associated with patient-derived genomic data. The
company’s GenePool solution is available as a platform-as-a-service
that provides customers with a rich set of built-in functionality
alongside seamless integrations with a growing ecosystem of
cloud-based storage, compute, and data processing technologies.
Armed with GenePool, customers in translational research,
biopharmaceutical, and clinical testing environments are maximizing
value from their genomics information with an efficient and
effective software infrastructure. Station X was founded by experts
in commercial bioinformatics technology who bring decades of
collective expertise to support the company’s global customers. For
more information, please visit www.stationxinc.com.
About Circulogene Theranostics
Headquartered in Birmingham, Ala., Circulogene Theranostics is
an innovative molecular diagnostics company founded and operated by
a team of experienced industry executives and skilled molecular
diagnostics scientists. Applying its proprietary laboratory
developed test for cfDNA liquid biopsies, Circulogene has developed
the first droplet-volume, next-generation sequencing (NGS) method
to provide full genomic load analysis, enabling more accurate data
to help clinicians and their patients. For more information,
visit www.circulogene.com or call 205-278-1600.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151201005702/en/
Station X, Inc.Media:Colin Sanford,
415-870-9188colin.sanford@W2comm.com